Caribou Biosciences, Inc.

CRBU

Caribou Biosciences, Inc.

CRBU

Insider Sentiment (TTM):

Last Purchase:2025-03-14Last Sale:2026-02-25Shares Purchased (TTM):0Shares Sold (TTM):24,317

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:35,758,941Shares Outstanding:95,861,716Institutional Ownership Pct.:37.30%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	26	12	12	11	25	29	16	32	38	49	51	104
Available For Sale Securities Debt Securities Curr…	86	106	127	136	159	179	193	196	224	245	278	234
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	0	1	0	1
Contract With Customer Asset Net Current	1	1	1	1	1	1	1	1	1	1	1	2
Other Receivables	-	1	2	2	2	2	2	2	2	2	2	2
Prepaid Expense And Other Assets Current	2	2	3	5	6	6	7	7	6	7	6	7
Assets Current	117	122	145	156	193	217	219	237	271	305	339	351
Assets Noncurrent
Equity Method Investments	-	-	0	0	0	9	9	9	9	8	8	8
Available For Sale Securities Debt Securities Nonc…	2	1	4	12	0	4	40	53	50	52	44	58
Property Plant And Equipment Net	5	6	7	8	8	19	19	20	20	19	18	17
Operating Lease Right Of Use Asset	17	17	18	16	16	20	20	20	21	22	22	23
Other Assets Noncurrent	2	2	2	4	4	5	6	5	2	2	2	2
Assets	143	149	175	195	221	274	313	344	373	407	432	458
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	4	6	4	3	4	2	3	3	6	3	2
Accrued Liabilities Current	13	14	17	19	21	20	24	25	24	19	21	18
Operating Lease Liability Current	1	1	1	3	2	2	1	1	1	1	1	1
Contract With Customer Liability Current	0	1	2	2	3	3	3	3	3	3	3	3
Liabilities Current	18	20	25	28	29	28	31	32	31	29	28	25
Liabilities Noncurrent
Contract With Customer Liability Noncurrent	1	2	2	2	2	3	3	4	5	5	6	7
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	-	-	-	-	10
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	-	0
Operating Lease Liability Noncurrent	25	26	26	23	24	24	25	25	26	26	26	26
Deferred Income Tax Liabilities Net	-	-	0	1	1	1	1	1	1	1	1	0
Liabilities	45	47	53	53	55	56	60	63	62	64	64	59
Stockholders Equity
Preferred Stock Value	-	-	-	-	-	-	-	-	-	-	-	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	744	724	719	712	709	705	701	693	689	684	668	664
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	1	-0	-0	0	-1
Retained Earnings Accumulated Deficit	-646	-622	-597	-570	-542	-488	-448	-413	-378	-341	-299	-265
Stockholders Equity	98	102	122	142	166	217	253	281	310	343	368	398
Liabilities And Stockholders Equity	143	149	175	195	221	274	313	344	373	407	432	458
Related Party	-	-	0	-1	0	2	0	0	0	2	2	-5
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	106	97	95	93	93	93	92	91	90	90	88	88
Shares Outstanding	106	97	95	93	93	93	92	91	90	90	88	88

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	25.53%	-10.64%	-16.49%	-	-	-	-	-	-	-	-	-
2025	34.18%	59.49%	188.61%	4.47%	26.82%	35.20%	-15.93%	-29.65%	-37.61%	4.09%	24.56%	22.81%
2024	-22.79%	-56.03%	-33.24%	10.49%	1.28%	-9.46%	-20.36%	-39.27%	-45.09%	-30.50%	-20.36%	-4.07%
2023	-	-	-	-	-	-	19.29%	20.13%	14.47%	-37.67%	-47.78%	-60.11%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.49	6.22	5.71	5.54	6.66	7.63	7.16	7.38	8.75	10.49	11.97	14.27
Quick Ratio	6.36	6.10	5.60	5.35	6.46	7.41	6.94	7.18	8.55	10.25	11.75	13.98
Working Capital	98.62M	102.71M	119.82M	127.45M	163.62M	188.83M	188.73M	205.27M	239.94M	275.49M	310.54M	326.12M
Leverage & Debt
Debt to Equity	0.46	0.46	0.44	0.37	0.33	0.26	0.24	0.22	0.20	0.19	0.17	0.15
Debt Ratio	0.31	0.32	0.30	0.27	0.25	0.21	0.19	0.18	0.17	0.16	0.15	0.13
Efficiency & Turnover
Asset Turnover TTM	0.06	0.05	0.05	0.03	0.03	0.03	0.03	0.03	0.09	0.09	0.09	0.08
Days Sales Outstanding TTM	4.98	5.13	5.46	8.36	5.72	18.49	7.54	20.95	5.41	13.39	1.85	8.07
Receivables Turnover TTM	73.25	71.13	66.82	43.64	63.78	19.74	48.40	17.43	67.51	27.27	197.01	45.24
Per Share Metrics
Diluted EPS TTM	-1.02	-1.39	-1.59	-1.68	-1.77	-1.60	-1.65	-1.64	-1.37	-1.29	-1.38	-1.13
Free Cash Flow Per Share TTM	-1.06	-1.07	-1.22	-0.98	-1.07	-1.53	-1.58	-1.45	-1.45	-1.27	-1.42	-1.29
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-1,090.90%	-1,175.68%	-1,329.37%	-1,708.08%	-1,837.56%	-1,648.79%	-1,667.16%	-1,439.50%	-427.56%	-392.00%	-336.63%	-315.49%
Net Profit Margin TTM	-1,030.42%	-1,189.14%	-1,327.40%	-1,690.45%	-1,800.93%	-1,490.84%	-1,491.95%	-1,290.81%	-372.78%	-345.05%	-296.05%	-273.19%
Growth Metrics
Net Revenue Growth (1Y)	10.02%	12.96%	11.66%	-19.00%	-72.45%	-70.31%	-71.01%	-66.85%	132.34%	127.41%	148.91%	141.97%
Net Income Growth (1Y)	-37.05%	-9.90%	-0.66%	6.08%	33.07%	28.29%	46.08%	56.65%	11.01%	6.35%	2.66%	-9.14%
EPS Growth (1Y)	-42.01%	-12.89%	-3.92%	2.85%	29.23%	23.61%	19.38%	45.10%	-24.53%	-27.13%	-15.43%	-33.97%
Valuation Metrics
P/E TTM	-1.72	-1.37	-1.00	-1.38	-0.71	-0.57	-0.96	-1.20	-1.20	-3.98	-4.14	-4.24
P/B TTM	1.81	1.79	1.22	1.53	0.71	0.39	0.57	0.63	0.48	1.34	1.15	1.01
P/S TTM	17.71	16.26	13.31	23.39	12.85	8.53	14.37	15.45	4.47	13.74	12.27	11.57
Market Cap	177.73M	182.14M	148.49M	217.37M	117.22M	84.62M	143.61M	177.29M	148.16M	459.02M	422.92M	400.49M
Enterprise Value	151.54M	170.03M	136.08M	206.18M	91.97M	55.15M	127.27M	145.28M	110.25M	409.62M	371.71M	296.43M
Calculated Values
Free Cash Flow TTM	-106.61M	-102.89M	-113.60M	-91.21M	-99.25M	-142.20M	-143.08M	-130.75M	-130.95M	-113.59M	-104.90M	-108.05M
Net Debt	-26.19M	-12.10M	-12.41M	-11.19M	-25.25M	-29.46M	-16.34M	-32.02M	-37.91M	-49.40M	-51.21M	-104.06M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-25Sale

Owner: Kelly, Timothy P

Title: Chief Technology Officer

Shares: 6,228

Price/Share: $1.93

Value: $12,020.04

Shares Owned: 73,125

Relationship: Officer

Ownership: Direct

2026-02-24Sale

Owner: Khan, Ruhi Ahmad

Title: Chief Business Officer

Shares: 6,938

Price/Share: $1.96

Value: $13,598.48

Shares Owned: 104,998

Relationship: Officer

Ownership: Direct

2026-02-24Sale

Owner: Mcclung, Barbara G

Title: Chief Legal Officer

Shares: 6,938

Price/Share: $1.96

Value: $13,598.48

Shares Owned: 481,564

Relationship: Officer

Ownership: Direct

2026-02-24Sale

Owner: Albertson, Tina M.

Title: Chief Medical Officer

Shares: 1,066

Price/Share: $1.96

Value: $2,089.36

Shares Owned: 68,523

Relationship: Officer

Ownership: Direct

2026-02-24Sale

Owner: Kelly, Timothy P

Title: Chief Technology Officer

Shares: 3,147

Price/Share: $1.96

Value: $6,168.12

Shares Owned: 79,353

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-25	Kelly, Timothy P	Officer	Chief Technology Officer	Direct	Sale	6,228	1.93	$12,020.04	73,125	4
2026-02-24	Khan, Ruhi Ahmad	Officer	Chief Business Officer	Direct	Sale	6,938	1.96	$13,598.48	104,998	4
2026-02-24	Mcclung, Barbara G	Officer	Chief Legal Officer	Direct	Sale	6,938	1.96	$13,598.48	481,564	4
2026-02-24	Albertson, Tina M.	Officer	Chief Medical Officer	Direct	Sale	1,066	1.96	$2,089.36	68,523	4
2026-02-24	Kelly, Timothy P	Officer	Chief Technology Officer	Direct	Sale	3,147	1.96	$6,168.12	79,353	4
2025-03-14	Haurwitz, Rachel E.	Director,Officer	President and CEO	Indirect	Purchase	20,000	1.02	$20,400.00	3,369,395	4
2025-02-21	Mcclung, Barbara G	Officer	Chief Legal Officer	Direct	Sale	3,564	1.35	$4,811.40	443,502	4
2025-02-21	Khan, Ruhi Ahmad	Officer	Chief Business Officer	Direct	Sale	3,564	1.35	$4,811.40	66,936	4
2025-02-21	Kanner, Steven	Officer	Chief Scientific Officer	Direct	Sale	3,564	1.35	$4,811.40	431,556	4
2025-01-29	Ryali, Sriram	Officer	Chief Financial Officer	Direct	Purchase	17,360	1.42	$24,651.20	17,360	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

37.30%

Inst. Shares: 35,758,941

Shares Outstanding: 95,861,716

2025-12-31

38.50%

Inst. Shares: 35,956,567

Shares Outstanding: 93,389,283

2025-09-30

39.02%

Inst. Shares: 36,402,150

Shares Outstanding: 93,293,099

2025-06-30

42.36%

Inst. Shares: 39,406,088

Shares Outstanding: 93,028,698

2025-03-31

52.71%

Inst. Shares: 48,855,700

Shares Outstanding: 92,679,493

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	35,758,941	95,861,716	37.30%
2025-12-31	35,956,567	93,389,283	38.50%
2025-09-30	36,402,150	93,293,099	39.02%
2025-06-30	39,406,088	93,028,698	42.36%
2025-03-31	48,855,700	92,679,493	52.71%
2024-12-31	57,640,423	90,317,925	63.82%
2024-09-30	51,822,791	90,455,900	57.29%
2024-06-30	52,692,462	90,340,932	58.33%
2024-03-31	65,654,780	89,302,937	73.52%
2023-12-31	67,847,676	73,807,597	91.93%
2023-09-30	70,082,707	83,783,992	83.65%
2023-06-30	43,526,316	61,417,934	70.87%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Caribou Biosciences, Inc. (CRBU) — SEC Financial Statements & Analysis

Caribou Biosciences, Inc. (CRBU) is a biological products, (no diagnostic substances) company, incorporated in DE. Caribou Biosciences, Inc. trades on Nasdaq as: CRBU. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Caribou Biosciences, Inc. reported a 10.02% year-over-year revenue growth, a Debt-to-Equity ratio of 0.46x, a Price-to-Sales (P/S) ratio of 17.71x (TTM), a Price-to-Book (P/B) ratio of 1.81x (TTM), at a market cap of $177.73M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 10.02%
Debt To Equity: 0.46x
P/S TTM: 17.71x
P/B TTM: 1.81x
Market Cap: $177.73M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Caribou Biosciences, Inc. in?

Caribou Biosciences, Inc. (CRBU) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CRBU's market cap?

Caribou Biosciences, Inc. (CRBU) has a market capitalization of $177.73M as of 2026-06-30.

What exchange does CRBU trade on?

Caribou Biosciences, Inc. (CRBU) trades on the Nasdaq.

Where is Caribou Biosciences, Inc. incorporated?

Caribou Biosciences, Inc. is incorporated in DE.